LGHL - GP LILM and IMVT are among pre market gainers
2023-07-17 08:53:44 ET
- Acumen Pharmaceuticals ( ABOS ) +103% to Hold Conference Call to Discuss Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s Disease.
- BridgeBio Pharma ( BBIO ) +66% announces consistently positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM).
- Nova LifeStyle ( NVFY ) +39% .
- argenx ( ARGX ) +27% report positive topline data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy.
- Healthcare Triangle ( HCTI ) +21% .
- PainReform ( PRFX ) +19% .
- GreenPower Motor Company ( GP ) +18% .
- Pardes Biosciences ( PRDS ) +14% enters into agreement to be acquired by MediPacific, Inc. for between $2.02 and $2.19 in Cash per Share Plus Contingent Value Rights.
- Coya Therapeutics ( COYA ) +12% reports additional proof-of-concept Clinical Biomarker data in patients with Alzheimer’s disease.
- Immunovant ( IMVT ) +11% .
- Universal Security Instruments ( UUU ) +10% Q4 earnings call release
- Zai Lab ( ZLAB ) +9% r eport positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy.
- Arcadia Biosciences ( RKDA ) +7% launches goodwheat into the breakfast category with new Better-For-You Pancake & Waffle Mixes and Single-Serve Quikcakes.
- Lilium ( LILM ) +7% .
- Sangamo Therapeutics ( SGMO ) +6% announces research evaluation and Option Agreement With Prevail, a wholly owned Subsidiary of Lilly, for Novel Engineered Capsids.
- Enveric Biosciences ( ENVB ) +6% r eports positive results from Animal Studies Demonstrating Oral Bioavailability and Well Tolerated Side Effect Profile for EB-373.
- Lion Group Holding ( LGHL ) +5% .
- Chewy ( CHWY ) +5% pops after Goldman Sachs points to strong growth trends and improved margins.
For further details see:
GP, LILM and IMVT are among pre market gainers